Effect of granulocyte colony-stimulating factor on IL-12 p40 production during chemotherapy for B-cell lineage non-Hodgkin's lymphoma patients

European Journal of Haematology

Volumn 77, Issue 5, 2006, Pages 403-409

  Toubai, Tomomi ^a   Tanaka, Junji ^a   Ota, Shuichi ^a   Fukuhara, Takashi ^b   Hashino, Satoshi ^a   Kondo, Takeshi ^a   Shono, Yusuke ^a   Morioka, Masanobu ^c   Kawamura, Tsugumichi ^d   Masauzi, Nobuo ^e   Kakinoki, Yasutaka ^f   Kobayashi, Hajime ^g   Kunieda, Yasuyuki ^h   Kasai, Masaharu ⁱ   Kurosawa, Mitsutoshi ^j   Asaka, Masahiro ^a   Imamura, Masahiro ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ASAHIKAWA CITY HOSPITAL   (Japan)

^c Department of Internal Medicine   (Japan)

^d HAKODATE CENTRAL GENERAL HOSPITAL   (Japan)

^e Hakodate City Hospital   (Japan)

^f Asahikawa Kosei Hospital   (Japan)

^g Obihiro Kosei Hospital   (Japan)

^h Wakkanai City Hospital   (Japan)

ⁱ SAPPORO HOKUYU HOSPITAL   (Japan)

^j Sapporo Kosei General Hospital   (Japan)

more..

Author keywords

Granulocyte colony stimulating factor; Interleukin 12; Interleukin 12 p35; Interleukin 12 p40; Non Hodgkin's lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12P40; INTERLEUKIN 12P70; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; HUMAN; LONG TERM CARE; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOWN-REGULATION; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; INTERLEUKIN-12 SUBUNIT P40; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREDNISONE; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 33749252168     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00746.x     Document Type: Article

References (42)

1. LAMONT AG, ADORINI L. IL-12: a key cytokine in immune regulation. Immunol Today 1996;17:214-217.
2. TRINCHIERI G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
3. TRINCHIERI G. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma). Curr Opin Immunol 1997;9:17-23.
4. BRUNDA MJ. Interleukin-12. J Leukoc Biol 1994;55:280-288.
5. ZOU JP, YAMAMOTO N, FUJII T, TAKENAKA H, KOBAYASHI M, HERRMANN SH, WOLF SF, FUJIWARA H, HAMAOKA T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 1995;7:1135-1145.
6. BRUNDA MJ, LUISTRO L, WARRIER RR, WRIGHT RB, HUBBARD BR, MURPHY M, WOLF SF, GATELY MK. Anti-tumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-1230.
7. ROBERTSON MJ, RITZ J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996;1:88-97.
8. OKAMURA H, TSUTSI H, KOMATSU T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
9. STERN AS, PODLASKI FJ, HULMES JD, et al. Purification to homogeneity and partial characterization of cytotoxic ltymphocyte maturation factor from human B- lymophoblastoid cells. Proc Natl Acad Sci USA 1990;87:6808-6812.
10. SIEBURTH D, JABS EW, WARRINGTON JA, LI X, LASOTA J, LAFORGIA S, KELLEHER K, HUEBNER K, WASMUTH JJ, WOLF SF. Assignment of genes encoding a unique cytokine (IL-12) composed of two unrelated subunits to chromosomes 3 and 5. Genomics 1992;14:59-62.
11. TRINCHIERI G. Interleukin -12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83-243.
12. MATTNER F, FISCHER S, GUCKES S, JIN S, KAULEN H, SCHMITT E, RUDE E, GERMANN T. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993;23:2202-2208.
13. GILLESSEN S, CARVAJAL D, LING P, PODLASKI FJ, STREMLO DL, FAMILLETTI PC, GUBLER U, PRESKY DH, STERN AS, GATELY MK. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 1995;25:200-206.
14. DEMETRI GD, GRIFFIN JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791-2808.
15. DALE DC, LILES WC, SUMMER WR, NELSON S. Review. Granulocyte colony-stimulating factor- role and relationships in infectious diseases. J Infect Dis 1995;172:1061-1075.
16. HARTUNG T, DOCKE WD, GANTNER F, KRIEGER G, SAUER A, STEVENS P, VOLK HD, WENDEL A. Effects of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995;85:2482-2489.
17. POLLMACHER T, KORTH C, MULLINGTON J, SCHREIBER W, SAUER J, VEDDER H, GALANOS C, HOLSBOER F. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996;87:900-905.
18. TOKI S, HIROMATSU K, AOKI Y, MAKINO M, YOSHIKAI Y. Protective effects of granulocyte colony-stimulating factor on endotoxin shock in mice with retrovirus-induced immunodeficiency syndrome. Cytokine 1997;9:781-786.
19. VILLA P, SHAKLEE CL, MEAZZA C, AGNELLO D, GHEZZI P, SENALDI G. Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J Infect Dis 1998;178:471-477.
20. WEISS M, MOLDAWER LL, SCHNEIDER EM. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 1999;93:425-439.
21. HARRIS NL, JAFFE ES, STEIN H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphomas study group. Blood 1994;84:1361-1392.
22. AIROLDI I, GUGLIELMINO R, GHIOTTO F, CORCIONE A, FACCHETTI P, TRUINI M, PISTOIA V. Cytokine gene in neoplastic B cells from human mantle cell, follicular, and marginal zone lymphomas and in their postulated normal counterparts. Cancer Res 2001;61:1285-1290.
23. AIROLDI I, GUGLIELMINO R, CARRA G, CORCIONE A, GEROSA F, TABORELLI G, TRINCHIERI G, PISTOIA V. The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes. Haematologica 2002;87:434-442.
24. SCHWALLER J, TOBLER A, NIKLAUS G, HURWITZ N, HENNIG I, FEY MF, BORISCH B. Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders. Blood 1995;85:2182-2188.
25. HSU SM, WALDRON JW Jr, HSU PL, HOUGH AJ Jr. Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol 1993;24:1040-1057.
26. FIOR R, VITA N, RAPHAEL M, MINTY A, MAILLOT MC, CREVON MC, CAPUT D, BIBERFELD P, FERRARA P, GALANAUD P. Interleukin-13 gene expression by malignant and EBV-transformed human B lymphocytes. Eur Cytokine Netw 1994;5:593-600.
27. FORD R, TAMAYO A, MARTIN B, NIU K, CLAYPOOL K, CABANILLAS F, AMBRUS J Jr. Identification of B-cell growth factors (interleukin-14; high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas. Blood 1995;86:283-293.
28. BOST KL, BIELIGK SC, JAFFE BM. Lymphokine m RNA expression by transplantable murine B lymphocytic malignancies. Tumor-derived IL-10 as a possible mechanism for modulating the anti-tumor response. J Immunol 1995;154:718-729.
29. BENJAMIN D, SHARMA V, KUBIN M, KLEIN JL, SARTORI A, HOLLIDAY J, TRINCHIERI G. IL-12 expression in AIDSrelated lymphoma B cell lines. J Immunol 1996;156:1626-1637.
30. JONES EA, PRINGLE JH, ANGEL CA, REES RC. Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leuk Lymphoma 2002;43:1313-1321.
31. ARPINATI M, GREEN CL, HEIMFELD S, HEUSER JE, ANASETTI C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000;95:2484-2490.
32. PAN L, DELMONTE J Jr, JALONEN CK, FERRARA JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995;86:4422-4429.
33. MIELCAREK M, MARTIN PJ, TOROK-STORB B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997;89:1629-1634.
34. MIELCAREK M, GRAF L, JOHNSON G, TOROK-STORB B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998;92:215-222.
35. EGI H, HAYAMIZU K, KITAYAMA T, OHMORI I, OKAJIMA M, ASAHARA T. Downreguration of both interleukin-12 and interleukin-2 in heart allografts by pretransplant host treatment with granulocyte colony-stimulating factor and tacrolimus. Cytokine 2002;18:164-167.
36. OHMORI I, HAYAMIZU K, KITAYAMA T, EGI H, AIHAITI X, ASAHARA T. Downreguration of interleukin-12p35 and upregulation of interleukin-12p40 mRNA expression in heart allografts by blood transfusion from granulocyte colony-stimulating factor-treated donos. Cytokine 2003;21:27-31.
37. KITAYAMA T, HAYAMIZU K, EGI H, OHMORI I, YOSHIMITSU M, ASAHARA T. Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine m RNA expression. Transplantation 2003;75:553-556.
38. GATELY MK, RENZETTI LM, MAGRAM J, STERN AS, ADORINI L, GUBLER U, PRESKY DH. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Ann Rev Immunol 1998;16:495-521.
39. KATO K, SHIMOZATO O, HOSHI K, WAKIMOTO H, HAMADA H, YAGITA H, OKUMURA K. Local production of the p40 subunit of interleukin 12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc Natl Acad Sci USA 1996;93:9085-9089.
40. ROTHE H, O'HARA RM Jr, MARTIN S, KOLB H. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12 (p40) 2. Diabetologia 1997;40:641-646.
41. HARTUNG T, DOECKE WD, BUNDSCHUH D, et al. Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Ther 1999;66:415-424.
42. DOORDUIJN JK, VAN DER HOLT B, VAN IMHOFF GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-3050.